Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s):  CLAZF

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.


TSXV:CLAS.H - Post by User

Comment by Captainblkon Feb 07, 2021 1:56pm
107 Views
Post# 32496232

RE:RE:RE:RE:This gives me less and less and less confidence

RE:RE:RE:RE:This gives me less and less and less confidence
AngelaL wrote:

As a matter of fact I did check. Salzman has published 157 scientific papers. It was easy to find on the web. 

https://pubmed.ncbi.nlm.nih.gov/?term=Salzman+al&show_snippets=off&sort=date&size=200



thanks for the link. this doesnt exactly prove he is famous (your words) or renowned though. doing a quick search in the link you provided shows that he has zero papers in the last year, 7 papers ni the last 10 years ( none of which he was a significant contributor, and none of those were in studies related to anything KLY has been involved in), while he has been a part of some papers that involved in Nitric Oxide, the last paper citing him as a contributor was in 2005- https://pubmed.ncbi.nlm.nih.gov/15753755/

most other NO papers are well over 20-30 years old

there is also the fact that almost anyone can thow a journal at the Pubmed wall, as they have become a stop for fake news and predatory journalism-
 

In a paper published in Neuroscience, the authors analyzing the neurology and neuroscience journals included in PubMed found that:

  • Twenty-five predatory neurology journals were indexed in PubMed, accounting for 24.7% of all predatory neurology journals.
  • Fourteen predatory neuroscience journals were indexed in PubMed, accounting for 16.1% of all predatory neuroscience journals.
  • Only one of the 188 predatory neuroscience or neurology journals appeared in the DOAJ index.
  • Only 54.6% of the journals deemed predatory in neuroscience actually contained articles.
https://www.bloomberg.com/news/features/2017-08-29/medical-journals-have-a-fake-news-problem


Do you have some other form of proof that might have more substance that may legitimize these guys a bit more? I am willing to explore it. again, not looking for puff pieces created by companies they/he have founded, Id like to see work ore medical breakthroughs he'd be famous for


 


 



<< Previous
Bullboard Posts
Next >>